Precigen Shares Outstanding 2012-2021 | PGEN

Precigen shares outstanding from 2012 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Precigen Annual Shares Outstanding
(Millions of Shares)
2020 167
2019 154
2018 130
2017 120
2016 118
2015 111
2014 99
2013 41
2012 6
2011 5
Precigen Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 199
2021-03-31 194
2020-12-31 167
2020-09-30 166
2020-06-30 164
2020-03-31 160
2019-12-31 154
2019-09-30 155
2019-06-30 154
2019-03-31 153
2018-12-31 130
2018-09-30 130
2018-06-30 129
2018-03-31 128
2017-12-31 120
2017-09-30 121
2017-06-30 120
2017-03-31 119
2016-12-31 118
2016-09-30 118
2016-06-30 118
2016-03-31 117
2015-12-31 111
2015-09-30 112
2015-06-30 109
2015-03-31 108
2014-12-31 99
2014-09-30 100
2014-06-30 99
2014-03-31 99
2013-12-31 41
2013-09-30 56
2013-06-30 6
2013-03-31 6
2012-12-31
2012-09-30 6
2012-06-30 5
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.116B $0.103B
Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29